Clinical AML prognosis and medication are dependent on specific gene mutations, such as TP53, FLT3, NPM1, DNMT3A, IDH1, IDH2, CEBPA, and PHF6 or specific chromosome translocations [8, 9], which are used to grade clinical risk. The gene discussed is TP53; the disease is acute myeloid leukemia.